Imagion CEO Bob Proulx discusses the company’s path to first-in-human trials plus early discussions with potential partners and strategic investors in this Margermarket article.
Read the article.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce